276 related articles for article (PubMed ID: 8873656)
21. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD
Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216
[TBL] [Abstract][Full Text] [Related]
22. TIMI grade flow, mortality, and the GUSTO-III trial.
Stringer KA
Pharmacotherapy; 1998; 18(4):699-705. PubMed ID: 9692644
[TBL] [Abstract][Full Text] [Related]
23. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction.
Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators
N Engl J Med; 1997 Jun; 336(23):1621-8. PubMed ID: 9173270
[TBL] [Abstract][Full Text] [Related]
24. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries.
Holmes DR; Califf RM; Topol EJ
J Am Coll Cardiol; 1995 Jun; 25(7 Suppl):10S-17S. PubMed ID: 7775708
[TBL] [Abstract][Full Text] [Related]
25. Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators.
Aylward PE; Wilcox RG; Horgan JH; White HD; Granger CB; Califf RM; Topol EJ
Ann Intern Med; 1996 Dec; 125(11):891-900. PubMed ID: 8967669
[TBL] [Abstract][Full Text] [Related]
26. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Granger CB; Becker R; Tracy RP; Califf RM; Topol EJ; Pieper KS; Ross AM; Roth S; Lambrew C; Bovill EG
J Am Coll Cardiol; 1998 Mar; 31(3):497-505. PubMed ID: 9502626
[TBL] [Abstract][Full Text] [Related]
27. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.
Kent DM; Hayward RA; Griffith JL; Vijan S; Beshansky JR; Califf RM; Selker HP
Am J Med; 2002 Aug; 113(2):104-11. PubMed ID: 12133748
[TBL] [Abstract][Full Text] [Related]
28. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
GUSTO Angiographic Investigators
N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
[TBL] [Abstract][Full Text] [Related]
29. Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators.
Goodman SG; Langer A; Ross AM; Wildermann NM; Barbagelata A; Sgarbossa EB; Wagner GS; Granger CB; Califf RM; Topol EJ; Simoons ML; Armstrong PW
Circulation; 1998 Feb; 97(5):444-50. PubMed ID: 9490238
[TBL] [Abstract][Full Text] [Related]
30. Streptokinase. A pharmacoeconomic appraisal of its use in the management of acute myocardial infarction.
Gillis JC; Goa KL
Pharmacoeconomics; 1996 Sep; 10(3):281-310. PubMed ID: 10163575
[TBL] [Abstract][Full Text] [Related]
31. Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Tardiff BE; Califf RM; Morris D; Bates E; Woodlief LH; Lee KL; Green C; Rutsch W; Betriu A; Aylward PE; Topol EJ
J Am Coll Cardiol; 1997 Feb; 29(2):240-9. PubMed ID: 9014973
[TBL] [Abstract][Full Text] [Related]
32. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial.
Califf RM; Pieper KS; Lee KL; Van De Werf F; Simes RJ; Armstrong PW; Topol EJ
Circulation; 2000 May; 101(19):2231-8. PubMed ID: 10811588
[TBL] [Abstract][Full Text] [Related]
33. Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy.
Labinaz M; Sketch MH; Ellis SG; Abramowitz BM; Stebbins AL; Pieper KS; Holmes DR; Califf RM; Topol EJ
Am Heart J; 2001 Mar; 141(3):469-77. PubMed ID: 11231447
[TBL] [Abstract][Full Text] [Related]
34. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.
Kalish SC; Gurwitz JH; Krumholz HM; Avorn J
J Gen Intern Med; 1995 Jun; 10(6):321-30. PubMed ID: 7562123
[TBL] [Abstract][Full Text] [Related]
35. Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial.
White HD
Am J Cardiol; 1998 Oct; 82(8B):57P-62P. PubMed ID: 9809893
[TBL] [Abstract][Full Text] [Related]
36. Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.
Barradell LB; Goa KL
Pharmacoeconomics; 1995 Nov; 8(5):428-59. PubMed ID: 10172669
[TBL] [Abstract][Full Text] [Related]
37. Thrombolysis in acute myocardial infarction: analysis of studies comparing accelerated t-PA and streptokinase.
Smith BJ
J Accid Emerg Med; 1999 Nov; 16(6):407-11. PubMed ID: 10572811
[TBL] [Abstract][Full Text] [Related]
38. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.
Lancet; 1990 Jul; 336(8707):65-71. PubMed ID: 1975321
[TBL] [Abstract][Full Text] [Related]
39. Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
Reiner JS; Lundergan CF; van den Brand M; Boland J; Thompson MA; Machecourt J; Py A; Pilcher GS; Fink CA; Burton JR
J Am Coll Cardiol; 1994 Nov; 24(6):1439-44. PubMed ID: 7930273
[TBL] [Abstract][Full Text] [Related]
40. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy.
Mahaffey KW; Granger CB; Collins R; O'Connor CM; Ohman EM; Bleich SD; Col JJ; Califf RM
Am J Cardiol; 1996 Mar; 77(8):551-6. PubMed ID: 8610601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
